Guides Collective
The Weekly Guide
Resources, research, and reflections — curated each week for the guides in our community.
JUL 10, 2026
From the Platform
What's new and coming to Guides Collective.
Calendar bug fixed! Your availability for intake calls should be synced to your google calendar now.
We're running national ads! The plan is to gather data from the first ads and refine our messaging in the next phase. Exciting.
Still much to do on the UX front for both seeker and guide dashboards. Once bugs are fixed we'll be updating the UX on both sides.
Section 01
Industry Headlines
What's happening in the psychedelic space this week.
BUSINESS WIRE · JULY 9, 2026
Definium's LSD Therapy Delivers "Profound" Results, Stock Soars 97%
Definium Therapeutics' LSD-based depression treatment produced Phase 3 results analysts called "profound," sending shares up 97% over the past month to roughly $45 apiece. The data adds to a wave of late-stage psychedelic trial wins pushing the sector toward its first FDA approvals.
MEDICAL XPRESS · JULY 9, 2026
Psilocybin Therapy Shows Potential as a Treatment for Anorexia Nervosa in Small Trial
A pilot study of 21 women with long-standing anorexia nervosa found that three psilocybin doses combined with psychotherapy were safe and well-tolerated. Eating disorder symptom severity decreased at every follow-up point, with 48% of participants reaching non-disorder symptom levels by three months.
AZ FREE NEWS · JULY 7, 2026
Hamadeh Introduces Bill Requiring Pentagon Review of Emerging PTSD Treatments for Veterans
Congressman Abe Hamadeh introduced legislation requiring the Department of Defense to formally assess emerging PTSD treatments, including psychedelic-assisted therapies, and report findings back to Congress. The bill builds on bipartisan momentum to expand healthcare options for veterans and service members with treatment-resistant PTSD, aligning with the White House's April executive order accelerating research into serious mental illness treatments.
Section 02
From the Field
Perspectives and insights from leaders in the psychedelic space.
THE DAILY CARDINAL · JULY 7, 2026
Psychedelic Research Gains Momentum Amid Federal Shift From Antidepressants
The federal government is accelerating psychedelic drug research while scrutinizing commonly prescribed antidepressants, positioning the University of Wisconsin-Madison's Usona Institute at the forefront of the shift. Researchers there are investigating whether psilocybin could serve as a cheaper, safer alternative to traditional SSRIs for treating depression.
THE MICRODOSE · JULY 10, 2026
Georgia's New Psychedelic Clinic Regulations Take Effect
Oregon's public health department will fold its psilocybin services program into its medical marijuana division by September, forming a single Oregon Psilocybin and Medical Cannabis Section to cut costs during a budget shortfall. The state has also proposed doubling industry fees as roughly half of its 39 licensed service centers have already closed or let their licenses lapse.
Section 03
Personal Journeys
First-person accounts worth reading — perspectives that inform the work we do.
THE WAR HORSE · JANUARY 8, 2026
Marc Dervaes Lost His Arm in Afghanistan. Ibogaine Helped Him Find Himself Again.
Afghanistan veteran Marc Dervaes traveled to a clinic in Mexico for ibogaine treatment to confront severe PTSD and alcohol addiction after losing his right arm in combat. After a second treatment, he says his mental health has improved dramatically — a rare second chance most veterans never get.
THE GREEN NURSE · JUNE 5, 2026
A Nurse's Own Psychedelic Healing Journey: Sherri Mack's Story
Registered nurse Sherri Mack spent years treating trauma and chronic illness in others before turning to psychedelic medicine to heal her own. Through careful, guided work with multiple substances, she moved from debilitation toward wholeness — and now teaches other clinicians what she learned along the way.